

India Human Papillomavirus Vaccine Market By Valence (Bivalent, Quadrivalent, Nonvalent, and Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, and Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, and Others), and By Region and Competition, Forecast & Opportunities, 2029

Market Report (3 business days) | 2023-10-03 | 90 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Multi-User License \$4500.00
- Custom Research License \$7500.00

Report description:

India human papillomavirus (HPV) vaccine market is anticipated to witness impressive growth during the forecast period. This can be ascribed due to the rise in HPV-related diseases, such as cervical cancer and other HPV-associated cancers, which have been increasing in India. This has led to an increased demand for Human Papillomavirus vaccines to prevent these diseases. Due to the increment in Cervical cancer, it has now become a significant health burden in India, with an estimated 96,922 new cases and 60,078 deaths in 2020. The increasing incidence of cervical cancer is driving demand for human papillomavirus vaccines as a preventative measure.

Nowadays, Indian people are adopting multi-valent human papillomavirus vaccines, which protect against several types of HPVs and offer broader protection against related diseases. The Indian government has also launched several vaccination programs to increase access to human papillomavirus vaccines, particularly in rural areas and among disadvantaged populations. These programs have helped to increase the demand for HPV vaccines in the country. With greater awareness about the health risks associated with HPV infections, there has been a growing demand for HPV vaccines among healthcare providers and patients. The availability of HPV vaccines has been increasing in India, particularly with the introduction of the government's vaccination programs. This has helped to increase access to HPV vaccines and has contributed to the growth of the market in India. The India

human papillomavirus vaccine market was approximately at USD 43.9 Million in 2020 and will probably reach USD 603.3 Million by 2027, expanding with a compound annual growth rate (CAGR) of 46.6% during the prophecy period.

Rising Prevalence of Cervical Cancer

In recent years, there has been a rising prevalence of cervical cancer in India, driven by various factors, such as low screening rates, limited access to healthcare services, and low awareness of cervical cancer prevention. Cervical cancer is the second most common cancer among women in India, accounting for approximately 14% of all female cancers. Nonetheless, the HPV vaccine has the potential to significantly reduce the incidence of cervical cancer in India, particularly if it is included in the national immunization program and made widely available.

The main reason behind cervical cancer is HPV infection, which is transmitted sexually. The HPV vaccine is highly effective in preventing HPV infections that cause most cases of cervical cancer. Several initiatives have been launched in India to increase awareness about cervical cancer prevention, including the importance of the human papillomavirus vaccine. The Indian government has also announced plans to introduce the HPV vaccine into the national immunization program, which is expected to increase access to the vaccine and reduce the burden of cervical cancer in the country. The rising prevalence of cervical cancer in India is a significant driver of the demand for human papillomavirus vaccines, and efforts to increase access and awareness about the vaccine are likely to play an important role in reducing the burden of this disease in the future.

Improvement In Healthcare Infrastructure

Improvements in healthcare infrastructure in India are expected to have a positive impact on the human papillomavirus vaccine market in the country, as they can increase access to healthcare services, including vaccination programs. Over the past few years, the Indian government has made significant efforts to improve healthcare infrastructure in the country. This includes initiatives, such as the Ayushman Bharat scheme, which aims to provide free health insurance coverage to millions of people in India, and the National Health Mission, which aims to provide universal access to quality healthcare services across the country. Infrastructural improvement can also lead to increased awareness about cervical cancer and the importance of HPV vaccination. For example, as more women in India have access to healthcare services, they may be more likely to receive cervical cancer screenings and learn about the importance of HPV vaccination as a preventive measure.

The availability of trained medical professionals also helps the market for the human papillomavirus vaccine in India to grow. With better healthcare infrastructure, the availability of trained medical professionals also increases. These medical professionals can be trained to administer human papillomavirus vaccines and educate patients about the vaccine and cervical cancer. Besides, improvements in healthcare infrastructure can also facilitate the delivery of HPV vaccines, such as through immunization programs and outreach efforts in rural areas. This can help to increase the uptake of the vaccine. Improvements in healthcare infrastructure are expected to be a key driver behind the growth in the India human papillomavirus vaccine market during the forecast period.

Increasing Access to Human Papillomavirus Vaccines in India

Improving access to human papillomavirus (HPV) vaccines is a key focus of the Indian government's efforts to prevent and control HPV-related diseases. Some of the initiatives aimed at increasing access to human papillomavirus vaccines in India include:

The Expanded National Immunization Program: The Government of India has expanded its National Immunization Program to include the human papillomavirus vaccine. The vaccine is currently recommended for girls aged 9 to 14 years and is provided free of cost in government-run healthcare facilities.

Public-Private Partnerships: The Government of India has established public-private partnerships to increase the availability and accessibility of human papillomavirus vaccines. These partnerships involve collaborations between government agencies, vaccine manufacturers, and non-governmental organizations (NGOs) to provide vaccines to underserved populations, such as those in rural areas.

Mobile Vaccination Units: To improve access to human papillomavirus vaccines in remote and underserved areas, the Government of India has launched mobile vaccination units. These units are equipped with vaccines and trained healthcare providers who visit schools and other community centers to administer the vaccines.

Awareness and Education Campaigns: The government of India has launched awareness and education campaigns to increase awareness about Human Papillomavirus and the importance of vaccination. These campaigns target parents, caregivers, and healthcare providers and aim to dispel myths and misconceptions about Human Papillomavirus vaccines.

International Partnerships: The government of India has formed partnerships with international organizations, such as the World Health Organization (WHO), to increase access to Human Papillomavirus vaccines. These partnerships involve the sharing of knowledge and best practices and the provision of technical assistance and financial support.

These initiatives have led to an increase in the availability and accessibility of human papillomavirus vaccines in India and are expected to contribute to the reduction of HPV-related diseases in the country and aid the human papillomavirus vaccine market in the country.

Growing Middle Class and Disposable Income

As the middle-class population in India grows, so does disposable income also increase, leading to greater access to healthcare services, including the Human Papillomavirus vaccine. With more disposable income, individuals may be more willing and able to pay for preventative healthcare measures, such as vaccines, that can protect them against diseases like cervical cancer. Also, the growing middle class in India is often accompanied by an increase in education and awareness about health-related issues. As individuals become more aware of the risks associated with cervical cancer and the benefits of the human papillomavirus vaccine, they may be more likely to seek out vaccination for themselves and their families. Besides, the rising middle class can also drive demand for higher quality healthcare services, which can include access to better and more effective vaccines, such as human papillomavirus vaccines. the growing middle class and disposable income in India can help to drive the India human papillomavirus vaccine market.

Market Segmentation

The India human papillomavirus vaccine market can be segmented by valence, disease indication, distribution channel, and region. By valence type, the market can be segmented into bivalent, quadrivalent, nonvalent, and others. By disease indication, the market can be segmented into vaginal cancer, penile cancer, vulvar cancer, cervical cancer, anal cancer, and others. By distribution channel, the market can be segmented into hospitals & clinics, governmental & non-governmental organizations, public & private alliances, and others. By Region, the market can be segmented into North India, South India, East India, and West India.

Market Players

GlaxoSmithKline Pharmaceuticals Limited, MSD Pharmaceuticals Private Limited, Serum Institute of India Pvt. Ltd., Bharat Biotech International Limited, HLL Lifecare Limited, and Panacea Biotec Ltd. are some of the market players in the India human papillomavirus vaccine market.

Report Scope:

In this report, the India human papillomavirus vaccine market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

□ India Human Papillomavirus Vaccine Market, By Valence:

- o Bivalent
- o Quadrivalent
- o Nonvalent

□ India Human Papillomavirus Vaccine Market, By Disease Indication:

- o Cervical Cancer
- o Anal Cancer
- o Vaginal Cancer
- o Penile Cancer
- o Vulvar Cancer

□ India Human Papillomavirus Vaccine Market, By Distribution Channel:

- o Hospitals & Clinics
- o Governmental & Non-Governmental Organizations
- o Public & Private Alliances

□ India Human Papillomavirus Vaccine Market, By Region:

- o North India
- o South India
- o East India
- o West India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India Human Papillomavirus Vaccine Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

□ Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Types
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3.0Executive Summary
- 3.1.0Overview of the Market
- 3.2.0Overview of Key Market Segmentations
- 3.3.0Overview of Key Market Players
- 3.4.0Overview of Key Regions/Countries
- 3.5.0Overview of Market Drivers, Challenges, and Trends
- 4.0Voice of Customer
- 5.0India Human Papillomavirus Market Outlook
 - 5.1.0Market Size & Forecast
 - 5.1.1.0By Value
 - 5.2.0Market Share & Forecast
 - 5.2.1.0By Valence (Bivalent, Quadrivalent, Nonvalent, Others)
 - 5.2.2.0By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others)
 - 5.2.3.0 By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others)
 - 5.2.4.0By Region (North India, South India, East India, West India)
- 6.0North Human Papillomavirus Vaccine Market Outlook
 - 6.1.0Market Size & Forecast
 - 6.1.1.0By Value
 - 6.2.0Market Share & Forecast
 - 6.2.1.0By Valence
 - 6.2.2.0By Disease Indication
 - 6.2.3.0By Distribution Channel
- 7.0South India Human Papillomavirus Vaccine Market Outlook
 - 7.1.0Market Size & Forecast
 - 7.1.1.0By Value
 - 7.2.0Market Share & Forecast
 - 7.2.1.0By Valence
 - 7.2.2.0By Disease Indication
 - 7.2.3.0By Distribution Channel
- 8.0East India Human Papillomavirus Vaccine Market Outlook
 - 8.1.0Market Size & Forecast
 - 8.1.1.0By Value
 - 8.2.0Market Share & Forecast
 - 8.2.1.0By Valence
 - 8.2.2.0By Disease Indication
 - 8.2.3.0By Distribution Channel
- 9.0West India Human Papillomavirus Vaccine Market Outlook
 - 9.1.0Market Size & Forecast
 - 9.1.1.0By Value
 - 9.2.0Market Share & Forecast
 - 9.2.1.0By Valence
 - 9.2.2.0By Disease Indication
 - 9.2.3.0By Distribution Channel
- 10.0Market Dynamics
 - 10.1.0Drivers
 - 10.2.0Challenges

- 11. Market Trends & Developments
 - 11.1. Merger & Acquisition
 - 11.2. Product Development
 - 11.3. Recent Developments
- 12. Policy & Regulatory Landscape
- 13. Porters Five Forces Analysis
 - 13.1. Competition in the Industry
 - 13.2. Potential of New Entrants
 - 13.3. Power of Suppliers
 - 13.4. Power of Customers
 - 13.5. Threat of Substitute Products
- 14. India Economic Profile
- 15. Competitive Landscape
 - 15.1. Business Overview
 - 15.2. Company Snapshot
 - 15.3. Products & Services
 - 15.4. Financials (As Reported)
 - 15.5. Recent Developments
 - 15.5.1. Bharat Biotech International Ltd.
 - 15.5.2. HLL Lifecare Limited
 - 15.5.3. Panacea Biotec Limited
 - 15.5.4. MSD Pharmaceuticals Private Limited
 - 15.5.5. Serum Institute of India
 - 15.5.6. GlaxoSmithKline Pharmaceuticals Ltd.
 - 16. Strategic Recommendations
- 17. About Us & Disclaimer

India Human Papillomavirus Vaccine Market By Valence (Bivalent, Quadrivalent, Nonvalent, and Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, and Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, and Others), and By Region and Competition, Forecast & Opportunities, 2029

Market Report (3 business days) | 2023-10-03 | 90 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Multi-User License	\$4500.00
	Custom Research License	\$7500.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*

Phone*

First Name*

Last Name*

Job title*

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-18"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com